Introduction
Phaeochromocytoma, primary aldosteronism and adrenal Cushing's syndrome are rare, but due to the secretion of excess catecholamines, mineralocorticoids, and glucocorticoids can result in serious morbidity and mortality.
The presenting features of phaeochromocytoma (hypertension, headache, sweating and palpitations) 1 are similar to non-pregnant women, but may be ascribed to preeclampsia or pregnancy. If phaeochromocytoma remains undiagnosed, maternal and fetal mortality can be as high as 40-50%. 2 Patients treated with alpha-adrenergic blockade 
Maternal medicine
have a lower maternal and fetal mortality. 3 Decisions about timing of surgery are made by a multidisciplinary team on a case by case basis. However, this is usually laparoscopic and may be undertaken during pregnancy, at the time of caesarean section or postnatally. 3 Primary aldosteronism (PA) presents with hypertension and hypokalaemic alkalosis due to autonomous production of aldosterone and secondary renin suppression. 4 The commonest management strategy during pregnancy is to use potassium supplements and antihypertensive drugs with deferral of surgery until after delivery. 5 Cushing's syndrome diagnosed in pregnancy is more commonly caused by an adrenal rather than a pituitary tumour. 2 Classical symptoms and signs of hypercortisolism (central weight gain, oedema, moon face, abdominal striae and hypertension) may occur in women with uncomplicated pregnancy and therefore the diagnosis of Cushing's syndrome can be difficult. 2 Pregnancy complicated by Cushing's syndrome can result in uncontrolled hypertension, associated with an increased risk of adverse outcomes for mother and fetus.
We aimed to undertake a prospective, national cohort study of the incidence, monitoring, management and outcomes of hormone-secreting adrenal tumours in pregnant women.
Methods
A national, prospective, observational cohort study was undertaken over 4 years (March 2011 to February 2015) using the UK Obstetric Surveillance System (UKOSS). UKOSS is a prospective monthly case collection scheme that includes all 202 consultant-led obstetric units in the UK. Women are not contacted directly and no personally identifiable information is collected. As all women with symptomatic adrenal tumours should have consultant-led care, we anticipate that the study is likely to have covered all cases within the entire UK birth cohort. The study was approved by the Riverside Ethics Committee, London (09/H0706/78).
Additional case ascertainment
The study was advertised at the UK Society for Endocrinology Annual Conference and all UK endocrinologists were contacted via email and by post to ask them to inform the study team of any pregnant women with adrenal tumours during the study period. No extra cases were identified.
Case definition
Cases were defined as women with a functioning hormonesecreting endocrine adrenal tumour, including women diagnosed pre-pregnancy who had not undergone surgery to remove the tumour. Inclusion criteria specified any woman with the diagnosis of phaeochromocytoma, primary aldosteronism or Cushing's syndrome due to an adrenal tumour; exclusion criteria included women with non-functioning adrenal tumours. Cases were only included if the diagnosis had been confirmed by a consultant endocrinologist.
Data collection
Cases that met the criteria for the study were identified by the obstetrician or endocrinologist responsible for their care. On reporting a case, the clinician was asked to complete a data collection form. Anonymised data were collected about adrenal tumour diagnosis, monitoring and management before pregnancy and antenatally, as well as maternal demographics, obstetric and medical history, delivery and perinatal outcomes. Cases were excluded if they did not meet the entry criteria (n = 16) (these cases included nine that were reported in error, three that were surgically treated prior to the reported pregnancy, two duplicates, one not confirmed by an endocrinologist and one where the reporter was unable to locate the hospital notes) or a data collection form was not returned (n = 2) (Figure 1 ). Clinical features of women with specific tumour types were compared with those reported in case reports or case series from the English language literature from 1985-2015, identified using a PubMed search (search terms: phaeochromocytoma, primary aldosteronism, Cushing's syndrome, endocrine tumours and pregnancy). When the data from previous systematic reviews were used, two separate researchers (G.Q. and K.R.) reviewed all articles, and individual cases common to more than one report were identified and excluded to ensure no individual case was compared twice. The majority of phaeochromocytoma cases were captured in two systematic reviews 3, 6 as well as in three additional case reports, 7-9 providing a total of 123 additional phaeochromocytomas for comparison. For primary aldosteronism there was one systematic review 10 as well as 15 individual cases, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] resulting in 34 cases for comparison. For Cushing's syndrome, there were two systematic reviews 25, 26 as well as two individual cases 9, 27 (156 cases in total). Demographic features of the adrenal tumour cases [maternal age, body mass index (BMI) and ethnic group] were compared with 2250 women in an established UKOSS database of pregnant controls, as previously described. 28 To establish whether adverse pregnancy outcome occurs more commonly in pregnancies complicated by adrenal tumours, two control groups were used for comparison ( Figure 1 ). The first was the UKOSS control group of 2250 women that was used for demographic comparisons. A second comparison group was obtained using information from the Office of National Statistics (ONS) in England for the years of the study. The ONS control group enabled comparison of the rates of rarer pregnancy outcomes in a large sample set. As the number of pregnancies complicated by adrenal tumours is small, these comparisons used outcome data from all cases in the literature from 1985-2015 in addition to pregnancy outcome data from the UKOSS adrenal tumour cases.
Statistical analyses
Statistical analysis was performed using STATA 12.1. P-values were considered significant if ≤0.05. For comparison of cases with UKOSS controls, the data relating to multiple pregnancies were removed. However, for ONS control data it was not possible to remove multiple pregnancies from the dataset. Incidence rates were estimated with 95% CI. Adjustment for variables such as maternal age or occupation was not possible due to small numbers. For categorical data, unadjusted risk ratios (RR) were used with Fisher's exact P-values (more appropriate than chisquare for smaller sample sizes).
Results
During the 4-year study period there were 15 cases of hormone-secreting adrenal tumours in pregnancy ( Figure 1 ) compared with 2 852 099 normal pregnancies, giving an overall incidence of hormone-secreting adrenal tumours in the UK of 0.53 per 100 000. The incidence rate for each individual tumour was: phaeochromocytoma 0.32 per 100 000, primary aldosteronism 0.11 per 100 000 and Cushing's syndrome 0.07 per 100 000. There were no significant differences in the age or BMI of women with any of the sub-types of adrenal tumours compared with controls (Table S1 ). The clinical features of each tumour type were considered in turn.
Phaeochromocytoma
The most common presenting features in the UKOSS phaeochromocytoma cases were palpitations (40%, 95% CI 12.2-73.7), headaches (20%, 95% CI 2.5-55.6) and hypertension (20%, 95% CI 2.5-55.6). The previously reported cases 3,7-10 had similar findings; palpitations affected 29.3% (95% CI 21.4-38.1) and headache affected 34.1% (95% CI 25.8-43.2). However, although the most noticeable feature in the previously reported cases was hypertension (73.9%, 95% CI 65.3-81.5), blood pressure control varied in the UKOSS cohort of women with phaeochromocytoma in pregnancy. The two cases that had been diagnosed prenatally had good control of blood pressure in pregnancy. Those diagnosed in pregnancy all had severe hypertension at the time of diagnosis, with systolic levels ranging from 140 to 190 mmHg and diastolic from 96 to 120 mmHg. Two women were diagnosed soon after delivery, and in these women the majority of blood pressure measurements during pregnancy were normal.
The most commonly administered medication to the women in whom phaeochromocytoma was diagnosed in pregnancy was phenoxybenzamine (70%, 95% CI 19.4-99.4) (Table S2) , and four were also prescribed a betablocker. One woman was treated with propranolol alone; this woman had poorly controlled, severe hypertension in the third trimester and was diagnosed as having a phaeochromocytoma at the time of delivery. Hence, use of a beta-blocker in isolation occurred before the diagnosis was made. In the literature, the most commonly administered medication was also phenoxybenzamine (62.1%, 95% CI 49.3-73.7), followed by atenolol (15.2%, 95% CI 7.5-26.1) and labetalol (15.2%, 95% CI 7.5-26.1) ( Table S2 ).
The timing of surgery for the UKOSS cases was primarily postpartum (60%, 95% CI 23.3-83.2). However, in the literature, surgery occurred at more varied times (16% in the 2nd trimester, 15% in the third trimester, 21% simultaneously with caesarean section and 35% postpartum). One of the 10 UKOSS cases had a previous diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type 2a.
Delivery outcomes were reported for six women from the UKOSS cohort (two cases had terminations of pregnancy and in two cases the outcomes were not reported). When combined with the cases in the literature, the mode of delivery was significantly more likely to be a caesarean section for women with phaeochromocytoma (RR 3.2, CI 2.81-3.64, P ˂ 0.001) than for controls ( Table 1) .
The mean gestational age at delivery for the UKOSS phaeochromocytoma cases was 35.7 weeks, (range 31-39 weeks' gestation). This was higher than the average gestational age at delivery of the women reported in the combined literature review of 32.1 weeks.
There was an increase in the rate of preterm delivery in women with phaeochromocytoma compared with UKOSS (RR 8.7, CI 6.9-10.9, P ˂ 0.001) and ONS (RR 8.2, CI 6.9-9.7, P ˂ 0.001) controls (Table 1) . There was also a significantly higher rate of stillbirth compared with both UKOSS (RR 25.8, CI 12.1-54.9, P ˂ 0.001) and ONS (RR 26.8, CI 16.7-43.0, P ˂ 0.001) controls. Furthermore, four of the eight women with phaeochromocytoma were admitted to the Intensive Care Unit (ICU) (50%, 95% CI 15.7-84.2), all of whom had surgery postpartum, and three of six infants were admitted to the neonatal ICU (50%, 95% CI 11.8-88.2).
Primary aldosteronism
There were three UKOSS cases of primary aldosteronism; in all cases, serum aldosterone was high and plasma renin levels low. Two women had hypokalaemia (K + < 3.4 mmol/l) prior to pregnancy as well as in their first trimester.
Presenting symptoms in the UKOSS cases included headache, dizziness and intermittent numbness of the hands and feet. In previously reported cases 10-24 the symptoms included headache, palpitations, muscle weakness, oedema, fatigue and nausea. All UKOSS cases had hypertension in the first trimester with systolic values ranging from 146 to 175 mmHg and diastolic values from 100 to 113 mmHg. One case had proteinuria (0.9 g/24 hours). All three cases were treated with anti-hypertensive medication. One case was treated with amiloride and by the third trimester had a normal blood pressure and serum potassium concentration. The other two cases continued to have elevated blood pressure despite three to five different anti-hypertension treatments. These findings are consistent with cases reported in the literature, with 88% presenting with blood pressures above 140/90 mmHg. When combined with the cases identified in the literature the most commonly prescribed medications for primary aldosteronism in pregnancy were methyldopa (55.6%, 95% CI 30.7-78.4) and labetalol (50%, 95% CI 26.1-73.9) in conjunction with a potassium supplement (55.6%, 95% CI 30.7-78.4) ( Table S3) .
None of the UKOSS cases had surgery during pregnancy. From the literature review, 40% (95% CI 16.3-67.7) of cases had surgery during the second trimester. Of the women that had surgical intervention, five proceeded to successful delivery at an average of 36 weeks' gestation. One woman in the literature suffered an intrauterine fetal death in the early third trimester, several weeks postlaparoscopic adrenalectomy. The remainder had surgery either postpartum (47%, 95% CI 21.2-73.4) or not at all (13%, 95% CI 1.6-40.4).
Of the three UKOSS cases with primary aldosteronism, two planned to have vaginal births and one had a caesarean section. The two cases that had planned vaginal deliveries were induced at 39 and 40 weeks' gestation due to raised blood pressure. When all cases in the literature and UKOSS cases were compared with UKOSS controls, women with primary aldosteronism were significantly more likely to have a caesarean section (RR 1.6, CI 1.08-2.5, P ˂ 0.001) ( Table 2) .
Women with primary aldosteronism in pregnancy also had increased rates of adverse pregnancy outcomes compared with the UKOSS controls and ONS controls ( Table 2 ). The mean gestational age at delivery was 36 weeks compared with a mean gestational age of 39.6 weeks in the UKOSS control group. Preterm deliveries were significantly more common in these women than in both the UKOSS controls (RR 8.03, CI 5.6-11.5, P < 0.001) and ONS controls (RR 7.5, CI 5.4-10.4, P < 0.001). In the literature, there were two stillbirths recorded among women with primary hyperaldosteronism, a significantly higher rate than both UKOSS (RR 11.68, CI 2.7-50.8, P = 0.016) and ONS (RR 12.2, CI 3.2-46.7, P = 0.012) controls.
Cushing's syndrome
There were two UKOSS cases of adrenal Cushing's syndrome; both presented with pregnancy-induced hypertension, headache and oedema. The commonest clinical features reported in the literature were hypertension (68.3%, 95% CI 59.9-75.8) followed by diabetes mellitus (25%, 95% CI 11.9-25.2). The UKOSS cases had severe hypertension with maximum systolic levels of 183-197 mmHg and diastolic pressures of 95-108 mmHg; one case had proteinuria. Both patients were administered anti-hypertensive drugs but these appeared to be relatively ineffective. However, while the most common medication used in the literature was metyrapone followed by ketoconazole, the UKOSS cases only received anti-hypertensive medication (Table S4 ).
Both UKOSS cases had laparoscopic unilateral adrenalectomy: in one it was performed 4 weeks post-miscarriage whereas in the other, it was performed at 28 weeks' gestation. In the literature, 4.9% (95% CI 2.0-9.8) had a bilateral adrenalectomy and 16.9% (95% CI 11.1-24.1) a unilateral adrenalectomy during pregnancy. Although the specific timings of the surgery were not given, there was an 87% live-birth rate from the cases that had unilateral or bilateral adrenalectomy.
One of the UKOSS cases had a successful pregnancy outcome, delivering a 36-week-old infant by induced labour. The other case had a fetal loss prior to surgery. When combined with the literature and compared with both control groups, women with Cushing's syndrome had a significantly higher risk of caesarean section (RR 3.3, CI 2.55-4.27, P < 0.001). They were also more likely to have preterm delivery than were the UKOSS controls (RR 7.32, CI 5.81-9.20, P < 0.001) or ONS controls (RR 6.86, CI 5.81-8.10, P < 0.001), and had a higher rate of stillbirth than the UKOSS controls (RR 11.65, CI 4.9-27.7, P < 0.001) and ONS controls (RR 12.11, CI 6.42-22.87, P < 0.001), and a 5-minute Apgar recording below 7 (RR 35.71, CI 13.01-98.03, P < 0.001) ( Table 3) .
Discussion

Main findings
The 4-year UKOSS cohort study of adrenal tumours in pregnancy provided an accurate estimate of the incidence of hormone-secreting adrenal tumours in pregnancy and confirmed that they are associated with high rates of maternal morbidity. Women with each type of tumour had severe hypertension, at levels consistent with increased rates of cerebral haemorrhage and death. Indeed, the UK Confidential Enquiry into Maternal Deaths recommends active treatment of maternal systolic blood pressures >150 mmHg. When the outcome data for the cases ascertained in this study were combined with those from all cases reported in the past 30 years, there were significantly increased rates of operative delivery, preterm labour and stillbirth. The presenting symptoms of palpitations and headache in women with phaeochromocytoma occurred at a similar frequency to that of other retrospective series, 3, 6 although the proportion of women with documented hypertension was lower, likely reflecting the paroxysmal nature of clinical features in people with phaeochromocytoma. In this series, women diagnosed during pregnancy had more severe hypertension than those in whom the diagnosis of phaeochromocytoma had been made prior to pregnancy, indicating that outcomes are improved with adequate alpha blockade. One of the UKOSS cases had MEN2a, highlighting the relevance of screening for germline mutations.
There are currently no randomised clinical trials that provide evidence about the drugs of first choice in pregnancy, although the general consensus is that women should be treated initially with alpha-adrenoreceptor blockade, and no fetal harm has been reported following the use of phenoxybenzamine in pregnancy. 29 The rates of caesarean section in women with phaeochromocytoma were significantly higher than in controls. In a previous study, vaginal delivery had a higher maternal mortality (31%) compared with caesarean section (19%). 1 Although there is no theoretical reason why a woman cannot undergo labour if she has adequate alphaadrenoreceptor blockade, it is recognised that women with phaeochromocytoma in pregnancy are at high risk of adverse outcomes, and this may have influenced decisions about the timing of delivery. The aetiology of fetal death is likely to relate to impaired placental function secondary to vasoconstriction in addition to the metabolic insults associated with co-existing gestational diabetes mellitus and preeclampsia.
In primary aldosteronism cases the most common presenting features were headache and hypertension, with recorded blood pressures of up to 190/120. A range of anti-hypertensive medications were administered, with methyldopa given most frequently.
One case in the UKOSS series was treated with amiloride and this woman had better blood pressure control in the third trimester compared with the other two cases with primary aldosteronism. She was also the only woman to have normokalaemia in late pregnancy. A previous case report of primary aldosteronism in pregnancy managed with amiloride noted it was a safe and effective agent in the non-surgical treatment of this disorder. 30 Therefore amiloride may be worth investigating as an effective alternative agent to spironolactone as a potassium-sparing anti-hypertension agent for women with primary aldosteronism in pregnancy.
Women with primary aldosteronism during pregnancy were more likely to have a caesarean section (38.8%, 95% CI 23.14-56.54). Maternal severe hypertension is likely to increase the risk of stillbirth, and electrolyte disturbances may also contribute.
There were two UKOSS cases of Cushing's syndrome, both with severe hypertension. Although gestational diabetes mellitus was not diagnosed in the UKOSS cases, in a review of 140 cases of Cushing's syndrome in pregnancy, 25% presented with diabetes mellitus. 26 Hypercortisolism in combination with hyperglycaemia increases the risk of having a miscarriage or a large-for-gestational-age or macrosomic infant. 26 The two most frequently used medications in the literature were metyrapone and ketoconazole. 25, 26 However, due to the small numbers of Cushing's syndrome cases in pregnancy, guidance is limited as regards the optimal treatment regimen.
Women with Cushing's syndrome had an increased incidence of caesarean section, premature birth and stillbirth. Women with Cushing's syndrome should be assessed for their eligibility for adrenal surgery, as a reduction in adverse maternal and neonatal outcomes has been reported following adrenalectomy during pregnancy. 26 
Strengths and limitations
The strength of this study is that all the UK obstetric units within the UK have been included. The study was advertised through the already established robust UKOSS system and at the national British Endocrine Society conference. All UK Consultant Endocrinologists registered with the BES also received email and newsletter correspondence about the study, so it is likely that there was effective identification of cases.
The limitations are that the numbers are small and to draw statistically robust conclusions using the UKOSS data, we would need to continue this prospective study for several years. As the number of cases recruited was small, we amalgamated our data with those obtained from previous reported studies. While this enabled us to study the impact of hormone-secreting tumours on the rate of adverse pregnancy outcomes, a limitation of this approach is that the outcomes of the UKOSS cases will have had less impact on the results than the outcomes reported in the larger number cases reported in previous studies. It is also possible that the current published literature has reporting bias with regard to the frequency of adverse outcomes.
Conclusions
Given that phaeochromocytoma, primary aldosteronism and Cushing's syndrome are associated with an increased risk of preterm delivery and stillbirth, careful monitoring is mandatory along with the development of a detailed multidisciplinary treatment plan. The new information obtained from this study may also be beneficial for pre-pregnancy counselling for these women.
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